Jump to ContentJump to Main Navigation
Show Summary Details
More options …

Hormone Molecular Biology and Clinical Investigation

Editor-in-Chief: Chetrite, Gérard S.

Editorial Board: Alexis, Michael N. / Baniahmad, Aria / Beato, Miguel / Bouillon, Roger / Brodie, Angela / Carruba, Giuseppe / Chen, Shiuan / Cidlowski, John A. / Clarke, Robert / Coelingh Bennink, Herjan J.T. / Darbre, Philippa D. / Drouin, Jacques / Dufau, Maria L. / Edwards, Dean P. / Falany, Charles N. / Fernandez-Perez, Leandro / Ferroud, Clotilde / Feve, Bruno / Flores-Morales, Amilcar / Foster, Michelle T. / Garcia-Segura, Luis M. / Gastaldelli, Amalia / Gee, Julia M.W. / Genazzani, Andrea R. / Greene, Geoffrey L. / Groner, Bernd / Hampl, Richard / Hilakivi-Clarke, Leena / Hubalek, Michael / Iwase, Hirotaka / Jordan, V. Craig / Klocker, Helmut / Kloet, Ronald / Labrie, Fernand / Mendelson, Carole R. / Mück, Alfred O. / Nicola, Alejandro F. / O'Malley, Bert W. / Raynaud, Jean-Pierre / Ruan, Xiangyan / Russo, Jose / Saad, Farid / Sanchez, Edwin R. / Schally, Andrew V. / Schillaci, Roxana / Schindler, Adolf E. / Söderqvist, Gunnar / Speirs, Valerie / Stanczyk, Frank Z. / Starka, Luboslav / Sutter, Thomas R. / Tresguerres, Jesús A. / Wahli, Walter / Wildt, Ludwig / Yang, Kaiping / Yu, Qi

4 Issues per year


CiteScore 2017: 2.48

SCImago Journal Rank (SJR) 2017: 1.021
Source Normalized Impact per Paper (SNIP) 2017: 0.830

Online
ISSN
1868-1891
See all formats and pricing
More options …
Volume 25, Issue 2

Issues

Hormones and endometrial carcinogenesis

Areege Kamal
  • Institute of Translational Medicine, Department of Women’s and Children’s Health, University of Liverpool, Liverpool, UK
  • The National Center for Early Detection of Cancer, Oncology Teaching Hospital, Baghdad Medical City, Baghdad, Iraq
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Nicola Tempest
  • Institute of Translational Medicine, Department of Women’s and Children’s Health, University of Liverpool, Liverpool, UK
  • Liverpool Women’s Hospital NHS Foundation Trust, Liverpool, UK
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Christina Parkes
  • Institute of Translational Medicine, Department of Women’s and Children’s Health, University of Liverpool, Liverpool, UK
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Rafah Alnafakh
  • Institute of Translational Medicine, Department of Women’s and Children’s Health, University of Liverpool, Liverpool, UK
  • Department of Pathology, Al-Hilla Teaching Hospital, Babil, Iraq
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Sofia Makrydima / Meera Adishesh / Dharani K. Hapangama
  • Corresponding author
  • Institute of Translational Medicine, Department of Women’s and Children’s Health, University of Liverpool, Liverpool, UK
  • Liverpool Women’s Hospital NHS Foundation Trust, Liverpool, UK
  • Email
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
Published Online: 2016-03-11 | DOI: https://doi.org/10.1515/hmbci-2016-0005

Abstract

Endometrial cancer (EC) is the commonest gynaecological cancer in the Western World with an alarmingly increasing incidence related to longevity and obesity. Ovarian hormones regulate normal human endometrial cell proliferation, regeneration and function therefore are implicated in endometrial carcinogenesis directly or via influencing other hormones and metabolic pathways. Although the role of unopposed oestrogen in the pathogenesis of EC has received considerable attention, the emerging role of other hormones in this process, such as androgens and gonadotropin-releasing hormones (GnRH) is less well recognised. This review aims to consolidate the current knowledge of the involvement of the three main endogenous ovarian hormones (oestrogens, progesterone and androgens) as well as the other hormones in endometrial carcinogenesis, to identify important avenues for future research.

Keywords: androgens; endometrial cancer; gonadotropin-releasing hormones; oestrogen; polycystic ovarian syndrome; progesterone

References

  • 1.

    Husing A, Dossus L, Ferrari P, Tjonneland A, Hansen L, Fagherazzi G, Baglietto L, Schock H, Chang-Claude J, Boeing H, Steffen A, Trichopoulou A, Bamia C, Katsoulis M, Krogh V, Palli D, Panico S, Onland-Moret NC, Peeters PH, Bueno-de-Mesquita HB, Weiderpass E, Gram IT, Ardanaz E, Obon-Santacana M, Navarro C, Sanchez-Cantalejo E, Etxezarreta N, Allen NE, Khaw KT, Wareham N, Rinaldi S, Romieu I, Merritt MA, Gunter M, Riboli E, Kaaks R. An epidemiological model for prediction of endometrial cancer risk in europe. Eur J Epidemiol 2016;31:51–60.CrossrefGoogle Scholar

  • 2.

    Anderson AS, Key TJ, Norat T, Scoccianti C, Cecchini M, Berrino F, Boutron-Ruault MC, Espina C, Leitzmann M, Powers H, Wiseman M, Romieu I. European code against cancer 4th edition: obesity, body fatness and cancer. Cancer Epidemiol 2015;39:Suppl 1:S34–45.CrossrefGoogle Scholar

  • 3.

    Lindemann K, Eskild A, Vatten LJ, Bray F. Endometrial cancer incidence trends in norway during 1953–2007 and predictions for 2008–2027. Int J Cancer 2010;127:2661–8.Google Scholar

  • 4.

    Iyer R, Gentry-Maharaj A, Liston R, Desai R, Gornall R, Leeson S, Linder A, Lopes A, Meechan D, Nevin J, TMould I, A Olaitan d, Rufford B, Shanbhag S, Thackeray A, Nick Wood SV, Reynolds K, Nordin A, MenonUsha. Gynaecological oncology surgical outcomes and complications (ukgosoc). ESGO 18. Liverpool2013.Google Scholar

  • 5.

    Cancer research uk, uk cancer incidence (2009) and mortality (2010) summary july 2012 european age-standardised (as) rates 2012 [cited 2015 July].Google Scholar

  • 6.

    Setiawan VW, Yang HP, Pike MC, McCann SE, Yu H, Xiang YB, Wolk A, Wentzensen N, Weiss NS, Webb PM, van den Brandt PA, van de Vijver K, Thompson PJ, Australian National Endometrial Cancer Study G, Strom BL, Spurdle AB, Soslow RA, Shu XO, Schairer C, Sacerdote C, Rohan TE, Robien K, Risch HA, Ricceri F, Rebbeck TR, Rastogi R, Prescott J, Polidoro S, Park Y, Olson SH, Moysich KB, Miller AB, McCullough ML, Matsuno RK, Magliocco AM, Lurie G, Lu L, Lissowska J, Liang X, Lacey JV, Jr., Kolonel LN, Henderson BE, Hankinson SE, Hakansson N, Goodman MT, Gaudet MM, Garcia-Closas M, Friedenreich CM, Freudenheim JL, Doherty J, De Vivo I, Courneya KS, Cook LS, Chen C, Cerhan JR, Cai H, Brinton LA, Bernstein L, Anderson KE, Anton-Culver H, Schouten LJ, Horn-Ross PL. Type i and ii endometrial cancers: have they different risk factors? J Clin Oncol 2013;31:2607–18.CrossrefGoogle Scholar

  • 7.

    Hanamura T, Niwa T, Gohno T, Kurosumi M, Takei H, Yamaguchi Y, Ito K-i, Hayashi S-i. Possible role of the aromatase-independent steroid metabolism pathways in hormone responsive primary breast cancers. Breast Cancer Res Treat 2014;143:69–80.CrossrefGoogle Scholar

  • 8.

    Tanaka S, Miki Y, Hashimoto C, Takagi K, Doe Z, Li B, Yaegashi N, Suzuki T, Ito K. The role of 5α-reductase type 1 associated with intratumoral dihydrotestosterone concentrations in human endometrial carcinoma. Mol Cell Endocrinol 2015;401:56–64.Google Scholar

  • 9.

    Limonta P, Montagnani Marelli M, Mai S, Motta M, Martini L, Moretti RM. Gnrh receptors in cancer: from cell biology to novel targeted therapeutic strategies. Endocr Rev 2012;33:784–811.CrossrefGoogle Scholar

  • 10.

    Emons G, Gorchev G, Harter P, Wimberger P, Stahle A, Hanker L, Hilpert F, Beckmann MW, Dall P, Grundker C, Sindermann H, Sehouli J. Efficacy and safety of aezs-108 (lhrh agonist linked to doxorubicin) in women with advanced or recurrent endometrial cancer expressing lhrh receptors: a multicenter phase 2 trial (ago-gyn5). Int J Gynecol Cancer 2014;24:260–5.CrossrefGoogle Scholar

  • 11.

    MA. V-D. The development of the uterus in late fetal life, infancy, and childhood. In: Norris HJ HA, Abell, MR, editors. The uterus. Baltimore, MD: Williams & Wilkins, 1973:40–67.Google Scholar

  • 12.

    Hapangama DK, Kamal AM, Bulmer JN. Estrogen receptor β: the guardian of the endometrium. Hum Reprod Update 2015;21:174–93.CrossrefGoogle Scholar

  • 13.

    Valentijn AJ, Palial K, Al-Lamee H, Tempest N, Drury J, Hapangama DK, Murray P, Von Zglinicki T, Saretzki G, Gargett CE. Ssea-1 isolates human endometrial basal glandular epithelial cells: phenotypic and functional characterization and implications in the pathogenesis of endometriosis. Hum Reprod 2013;28:2695–708.Google Scholar

  • 14.

    Chen SY, Huang YC, Liu SP, Tsai FJ, Shyu WC, Lin SZ. An overview of concepts for cancer stem cells. Cell Transplant 2011;20:113–20.CrossrefGoogle Scholar

  • 15.

    Hapangama D. Mifepristone: the multi-faceted anti-hormone. J Drug Eval 2003;1:149–75.Google Scholar

  • 16.

    Slayden D, Brenner RM. Hormonal regulation and localization of estrogen, progestin and androgen receptors in the endometrium of nonhuman primates: effects of progesterone receptor antagonists. Arch Histol Cytol 2004;67:393–409.CrossrefGoogle Scholar

  • 17.

    Wada-Hiraike O, Hiraike H, Okinaga H, Imamov O, Barros RP, Morani A, Omoto Y, Warner M, Gustafsson JA. Role of estrogen receptor beta in uterine stroma and epithelium: insights from estrogen receptor beta-/- mice. Proc Natl Acad Sci USA 2006;103:18350–5.CrossrefGoogle Scholar

  • 18.

    Lovely LP, Appa Rao KB, Gui Y, Lessey BA. Characterization of androgen receptors in a well-differentiated endometrial adenocarcinoma cell line (ishikawa). J Steroid Biochem Mol Biol 2000;74:235–41.CrossrefGoogle Scholar

  • 19.

    Apparao KB, Lovely LP, Gui Y, Lininger RA, Lessey BA. Elevated endometrial androgen receptor expression in women with polycystic ovarian syndrome. Biol Reprod 2002;66:297–304.CrossrefGoogle Scholar

  • 20.

    Labrie F. All sex steroids are made intracellularly in peripheral tissues by the mechanisms of intracrinology after menopause. J Steroid Biochem Mol Biol 2015;145:133–8.CrossrefGoogle Scholar

  • 21.

    Teulings FA, van Gilse HA, Henkelman MS, Portengen H, Alexieva-Figusch J. Estrogen, androgen, glucocorticoid, and progesterone receptors in progestin-induced regression of human breast cancer. Cancer Res 1980;40:2557–61.Google Scholar

  • 22.

    Kurman RJ, Ellenson LH, Ronnett BM. Pathology of the female genital tract [Online system or service]. Boston, MA: Springer Science+Business Media, LLC: Springer, 2011. Available from: http://search.ebscohost.com.ezproxy.liv.ac.uk/login.aspx?direct=true&db=cat00003a&AN=lvp.b2389878&site=eds-live&scope=site.

  • 23.

    Hapangama DK, Bulmer JN. Pathophysiology of heavy menstrual bleeding. Womens Health (Lond Engl). 2016;12:3–13.CrossrefGoogle Scholar

  • 24.

    Gargett CE, Chan RW, Schwab KE. Hormone and growth factor signaling in endometrial renewal: role of stem/progenitor cells. Mol Cell Endocrinol 2008;288:22–9.Google Scholar

  • 25.

    Kamal A, Bulmer J, DeCruze S, Stringfellow H, Martin-Hirsch P, Hapangama D. Androgen receptors are acquired by healthy postmenopausal endometrial epithelium and their subsequent loss in endometrial cancer is associated with poor survival. Br J Cancer 2016. doi: 10.1038/bjc.2016.16.CrossrefGoogle Scholar

  • 26.

    O’Lone R, Frith MC, Karlsson EK, Hansen U. Genomic targets of nuclear estrogen receptors. Mol Endocrinol 2004;18:1859–75.CrossrefGoogle Scholar

  • 27.

    Umayahara Y, Kawamori R, Watada H, Imano E, Iwama N, Morishima T, Yamasaki Y, Kajimoto Y, Kamada T. Estrogen regulation of the insulin-like growth factor i gene transcription involves an ap-1 enhancer. J Biol Chem 1994;269:16433–42.Google Scholar

  • 28.

    Pietras RJ, Mrquez-Garbn DC. Membrane-associated estrogen receptor signaling pathways in human cancers. Clin Cancer Res 2007;13:4672–6.CrossrefGoogle Scholar

  • 29.

    Kushner PJ, Agard DA, Greene GL, Scanlan TS, Shiau AK, Uht RM, Webb P. Estrogen receptor pathways to ap-1. J Steroid Biochem Mol Biol 2000;74:311–7.CrossrefGoogle Scholar

  • 30.

    Ray A, Prefontaine KE, Ray P. Down-modulation of interleukin-6 gene expression by 17 beta-estradiol in the absence of high affinity DNA binding by the estrogen receptor. J Biol Chem 1994;269:12940–6.Google Scholar

  • 31.

    Kato S, Endoh H, Masuhiro Y, Kitamoto T, Uchiyama S, Sasaki H, Masushige S, Gotoh Y, Nishida E, Kawashima H, Metzger D, Chambon P. Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase. Science 1995;270:1491–4.CrossrefGoogle Scholar

  • 32.

    Hewitt SC, Harrell JC, Korach KS. Lessons in estrogen biology from knockout and transgenic animals. Annu Rev Physiol 2005;67:285–308.CrossrefGoogle Scholar

  • 33.

    Zhang L, Xiaoping L, Lijun Z, Lifang Z, Guo Z, Jianliu W, Lihui W. Nongenomic effect of estrogen on the mapk signaling pathway and calcium influx in endometrial carcinoma cells. J Cell Biochem 2009;106:553–62.CrossrefGoogle Scholar

  • 34.

    He YY, Cai B, Yang YX, Liu XL, Wan XP. Estrogenic g protein-coupled receptor 30 signaling is involved in regulation of endometrial carcinoma by promoting proliferation, invasion potential, and interleukin-6 secretion via the mek/erk mitogen-activated protein kinase pathway. Cancer Sci 2009;100:1051–61.CrossrefGoogle Scholar

  • 35.

    Sasaki M, Dharia A, Oh BR, Tanaka Y, Fujimoto S, Dahiya R. Progesterone receptor b gene inactivation and cpg hypermethylation in human uterine endometrial cancer. Cancer Res 2001;61:97–102.Google Scholar

  • 36.

    Campan M, Weisenberger D, Laird P. DNA methylation profiles of female steroid hormone deriven human malignancy. Curr Top Microbiol Immunol 2006;310:141–78.Google Scholar

  • 37.

    Sasaki M, Kotcherguina L, Dharia A, Fujimoto S, Dahiya R. Cytosine-phosphoguanine methylation of estrogen receptors in endometrial cancer. Cancer Res 2001;61:3262–6.Google Scholar

  • 38.

    Wu H, Yupeng C, Jing L, Bin S, Ge W, Ying Z, Dan W, Ruifang L, Xia Y, Hua Z, Luyang S, Yongfeng S. Hypomethylation-linked activation of pax2 mediates tamoxifen-stimulated endometrial carcinogenesis. Nature 2005;438:981–7.Google Scholar

  • 39.

    Hayes CL, Spink DC, Spink BC, Cao JQ, Walker NJ, Sutter TR. 17 beta-estradiol hydroxylation catalyzed by human cytochrome p450 1b1. Proc Natl Acad Sci USA 1996;93:9776–81.CrossrefGoogle Scholar

  • 40.

    Ke H, Suzuki A, Miyamoto T, Kashima H, Shiozawa T. 4-hydroxy estrogen induces DNA damage on codon 130/131 of pten in endometrial carcinoma cells. Mol Cell Endocrinol 2015;400:71–7.Google Scholar

  • 41.

    Valentijn AJ, Saretzki G, Tempest N, Critchley HO, Hapangama DK. Human endometrial epithelial telomerase is important for epithelial proliferation and glandular formation with potential implications in endometriosis. Hum Reprod 2015;30:2816–28.Google Scholar

  • 42.

    Henderson TA, Saunders PT, Moffett-King A, Groome NP, Critchley HO. Steroid receptor expression in uterine natural killer cells. J Clin Endocrinol Metab 2003;88:440–9.CrossrefGoogle Scholar

  • 43.

    Kurita T, Young P, Brody JR, Lydon JP, O’Malley BW, Cunha GR. Stromal progesterone receptors mediate the inhibitory effects of progesterone on estrogen-induced uterine epithelial cell deoxyribonucleic acid synthesis. Endocrinology 1998;139:4708–13.CrossrefGoogle Scholar

  • 44.

    Franco HL, Rubel CA, Large MJ, Wetendorf M, Fernandez-Valdivia R, Jeong JW, Spencer TE, Behringer RR, Lydon JP, Demayo FJ. Epithelial progesterone receptor exhibits pleiotropic roles in uterine development and function. FASEB J. 2012;26:1218–27.CrossrefGoogle Scholar

  • 45.

    Li Q, Kannan A, DeMayo FJ, Lydon JP, Cooke PS, Yamagishi H, Srivastava D, Bagchi MK, Bagchi IC. The antiproliferative action of progesterone in uterine epithelium is mediated by hand2. Science 2011;331:912–6.Google Scholar

  • 46.

    Mathew D, Drury JA, Valentijn AJ, Vasieva O, Hapangama DK. In silico, in vitro and in vivo analysis identifies a potential role for steroid hormone regulation of foxd3 in endometriosis-associated genes. Hum Reprod 2016;31:345–54.Google Scholar

  • 47.

    Kurita T, Wang YZ, Donjacour AA, Zhao C, Lydon JP, O’Malley BW, Isaacs JT, Dahiya R, Cunha GR. Paracrine regulation of apoptosis by steroid hormones in the male and female reproductive system. Cell Death Differ 2001;8:192–200.CrossrefGoogle Scholar

  • 48.

    Schindler AE. Progestogen deficiency and endometrial cancer risk. Maturitas 2009;62:334–7.CrossrefGoogle Scholar

  • 49.

    Fanta M. Is polycystic ovary syndrome, a state of relative estrogen excess, a real risk factor for estrogen-dependant malignancies? Gynecol Endocrinol 2013;29:145–7.CrossrefGoogle Scholar

  • 50.

    Park JC, Lim SY, Jang TK, Bae JG, Kim JI, Rhee JH. Endometrial histology and predictable clinical factors for endometrial disease in women with polycystic ovary syndrome. Clin Exp Reprod Med 2011;38:42–6.CrossrefGoogle Scholar

  • 51.

    Dumesic DA, Lobo RA. Cancer risk and pcos. Steroids 2013;78:782–5.CrossrefGoogle Scholar

  • 52.

    Holm NS, Glintborg D, Andersen MS, Schledermann D, Ravn P. The prevalence of endometrial hyperplasia and endometrial cancer in women with polycystic ovary syndrome or hyperandrogenism. Acta Obstet Gynecol Scand 2012;91:1173–6.CrossrefGoogle Scholar

  • 53.

    Shao R, Li X, Feng Y, Lin JF, Billig H. Direct effects of metformin in the endometrium: a hypothetical mechanism for the treatment of women with pcos and endometrial carcinoma. J Exp Clin Cancer Res 2014;33:41.CrossrefGoogle Scholar

  • 54.

    Gibson DA, Simitsidellis I, Collins F, Saunders PT. Evidence of androgen action in endometrial and ovarian cancers. Endocr Relat Cancer 2014;21:T203–18.CrossrefGoogle Scholar

  • 55.

    Bulun SE, Lin Z, Imir G, Amin S, Demura M, Yilmaz B, Martin R, Utsunomiya H, Thung S, Gurates B, Tamura M, Langoi D, Deb S. Regulation of aromatase expression in estrogen-responsive breast and uterine disease: from bench to treatment. Pharmacol Rev 2005;57:359–83.CrossrefGoogle Scholar

  • 56.

    Gao C, Wang Y, Tian W, Zhu Y, Xue F. The therapeutic significance of aromatase inhibitors in endometrial carcinoma. Gynecol Oncol 2014;134:190–5.CrossrefGoogle Scholar

  • 57.

    Zakharov V, Lin HK, Azzarello J, McMeekin S, Moore KN, Penning TM, Fung KM. Suppressed expression of type 2 3α/type 5 17β-hydroxysteroid dehydrogenase (akr1c3) in endometrial hyperplasia and carcinoma. Int J Clin Exp Pathol 2010;3:608–17.Google Scholar

  • 58.

    Pereira de Jésus-Tran K, Côté P-L, Cantin L, Blanchet J, Labrie F, Breton R. Comparison of crystal structures of human androgen receptor ligand-binding domain complexed with various agonists reveals molecular determinants responsible for binding affinity. Protein Sci 2006;15:987–99.CrossrefGoogle Scholar

  • 59.

    Berstein L, Kovalevskij A, Zimarina T, Maximov S, Gershfeld E, Vasilyev D, Baisheva S, Baymakhasheva A, Thijssen JH. Aromatase and comparative response to its inhibitors in two types of endometrial cancer. J Steroid Biochem Mol Biol 2005;95:71–4.CrossrefGoogle Scholar

  • 60.

    Kang JL, Wang DY, Wang XX, Yu J. Up-regulation of apoptosis by gonadotrophin-releasing hormone agonist in cultures of endometrial cells from women with symptomatic myomas. Hum Reprod 2010;25:2270–5.CrossrefGoogle Scholar

  • 61.

    Engel JB, Schally AV, Buchholz S, Seitz S, Emons G, Ortmann O. Targeted chemotherapy of endometrial, ovarian and breast cancers with cytotoxic analogs of luteinizing hormone-releasing hormone (lhrh). Arch Gynecol Obstet 2012;286:437–42.CrossrefGoogle Scholar

  • 62.

    Noci I, Pillozzi S, Lastraioli E, Dabizzi S, Giachi M, Borrani E, Wimalasena J, Taddei GL, Scarselli G, Arcangeli A. Hlh/hcg-receptor expression correlates with in vitro invasiveness in human primary endometrial cancer. Gynecol Oncol 2008;111:496–501.CrossrefGoogle Scholar

  • 63.

    Pillozzi S, Fortunato A, De Lorenzo E, Borrani E, Giachi M, Scarselli G, Arcangeli A, Noci I. Over-expression of the lh receptor increases distant metastases in an endometrial cancer mouse model. Front Oncol 2013;3:285.CrossrefGoogle Scholar

  • 64.

    Yurkovetsky Z, Ta’asan S, Skates S, Rand A, Lomakin A, Linkov F, Marrangoni A, Velikokhatnaya L, Winans M, Gorelik E, Maxwell GL, Lu K, Lokshin A. Development of multimarker panel for early detection of endometrial cancer. High diagnostic power of prolactin. Gynecol Oncol 2007;107:58–65.CrossrefGoogle Scholar

  • 65.

    Fader AN, Arriba LN, Frasure HE, von Gruenigen VE. Endometrial cancer and obesity: epidemiology, biomarkers, prevention and survivorship. Gynecol Oncol 2009;114:121–7.CrossrefGoogle Scholar

  • 66.

    Yamazawa K, Matsui H, Seki K, Sekiya S. A case-control study of endometrial cancer after antipsychotics exposure in premenopausal women. Oncology 2003;64:116–23.CrossrefGoogle Scholar

  • 67.

    Gurer-Orhan H, Suzen S. Melatonin, its metabolites and its synthetic analogs as multi-faceted compounds: antioxidant, prooxidant and inhibitor of bioactivation reactions. Curr Med Chem 2015;22:490–9.CrossrefGoogle Scholar

  • 68.

    Zamfir Chiru AA, Popescu CR, Gheorghe DC. Melatonin and cancer. J Med Life 2014;7:373–4.Google Scholar

  • 69.

    Ekmekcioglu C. Expression and putative functions of melatonin receptors in malignant cells and tissues. Wien Med Wochenschr 2014;164:472–8.CrossrefGoogle Scholar

  • 70.

    Viswanathan AN, Hankinson SE, Schernhammer ES. Night shift work and the risk of endometrial cancer. Cancer Res 2007;67:10618–22.CrossrefGoogle Scholar

  • 71.

    Ciortea R, Costin N, Braicu I, Haragas D, Hudacsko A, Bondor C, Mihu D, Mihu CM. Effect of melatonin on intra-abdominal fat in correlation with endometrial proliferation in ovariectomized rats. Anticancer Res 2011;31:2637–43.Google Scholar

  • 72.

    Bokhman JV. Two pathogenetic types of endometrial carcinoma. Gynecol Oncol 1983;15:10–7.CrossrefGoogle Scholar

  • 73.

    Sherman ME. Theories of endometrial carcinogenesis: a multidisciplinary approach. Mod Pathol 2000;13:295–308.CrossrefGoogle Scholar

  • 74.

    McConechy MK, Ding JR, Cheang MC, Wiegand KC, Senz J, Tone AA, Yang WN, Prentice LM, Tse K, Zeng T, McDonald H, Schmidt AP, Mutch DG, McAlpine JN, Hirst M, Shah SP, Lee CH, Goodfellow PJ, Gilks CB, Huntsman DG. Use of mutation profiles to refine the classification of endometrial carcinomas. J Pathol 2012;228:20–30.Google Scholar

  • 75.

    Lax SF, Kendall B, Tashiro H, Slebos RJ, Hedrick L. The frequency of p53, k-ras mutations, and microsatellite instability differs in uterine endometrioid and serous carcinoma: evidence of distinct molecular genetic pathways. Cancer 2000;88:814–24.CrossrefGoogle Scholar

  • 76.

    Voss MA, Ganesan R, Ludeman L, McCarthy K, Gornall R, Schaller G, Wei W, Sundar S. Should grade 3 endometrioid endometrial carcinoma be considered a type 2 cancer–a clinical and pathological evaluation. Gynecol Oncol 2012;124:15–20.CrossrefGoogle Scholar

  • 77.

    Zannoni GF, Monterossi G, De Stefano I, Gargini A, Salerno MG, Farulla I, Travaglia D, Vellone VG, Scambia G, Gallo D. The expression ratios of estrogen receptor alpha (eralpha) to estrogen receptor beta1 (erbeta1) and eralpha to erbeta2 identify poor clinical outcome in endometrioid endometrial cancer. Hum Pathol 2013;44:1047–54.Google Scholar

  • 78.

    Reid-Nicholson M, Iyengar P, Asher M, Soslow RA, Hummer AJ, Linkov I. Immunophenotypic diversity of endometrial adenocarcinomas: implications for differential diagnosis. Mod Pathol 2006;19:1091–100.Google Scholar

  • 79.

    Murali R, Soslow RA, Weigelt B. Classification of endometrial carcinoma: more than two types. Lancet Oncol 2014;15:e268–e78.CrossrefGoogle Scholar

  • 80.

    Cancer Genome Atlas Research N, Kandoth C, Schultz N, Cherniack AD, Akbani R, Liu Y, Shen H, Robertson AG, Pashtan I, Shen R, Benz CC, Yau C, Laird PW, Ding L, Zhang W, Mills GB, Kucherlapati R, Mardis ER, Levine DA. Integrated genomic characterization of endometrial carcinoma. Nature 2013;497:67–73.CrossrefGoogle Scholar

  • 81.

    Talhouk A, McConechy MK, Leung S, Li-Chang HH, Kwon JS, Melnyk N, Yang W, Senz J, Boyd N, Karnezis AN, Huntsman DG, Gilks CB, McAlpine JN. A clinically applicable molecular-based classification for endometrial cancers. Br J Cancer 2015;113:299–310.CrossrefGoogle Scholar

  • 82.

    McPherson CP, Sellers TA, Potter JD, Bostick RM, Folsom AR. Reproductive factors and risk of endometrial cancer. The iowa women’s health study. Am J Epidemiol 1996;143:1195–202.CrossrefGoogle Scholar

  • 83.

    Fearnley EJ, Marquart L, Spurdle AB, Weinstein P, Webb PM. Polycystic ovary syndrome increases the risk of endometrial cancer in women aged less than 50 years: an australian case-control study. Cancer Causes Control 2010;21:2303–8.CrossrefGoogle Scholar

  • 84.

    Gottschau M, Kjaer SK, Jensen A, Munk C, Mellemkjaer L. Risk of cancer among women with polycystic ovary syndrome: a danish cohort study. Gynecol Oncol 2015;136:99–103.CrossrefGoogle Scholar

  • 85.

    Haoula Z, Salman M, Atiomo W. Evaluating the association between endometrial cancer and polycystic ovary syndrome. Hum Reprod 2012;27:1327–31.CrossrefGoogle Scholar

  • 86.

    Li X, Feng Y, Lin JF, Billig H, Shao R. Endometrial progesterone resistance and pcos. J Biomed Sci 2014;21:2.CrossrefGoogle Scholar

  • 87.

    Thornton EC, Von Wald T, Hansen K. Polycystic ovarian syndrome: a primer. S D Med 2015;68:257–61.Google Scholar

  • 88.

    Aghajanova L, Velarde MC, Giudice LC. Altered gene expression profiling in endometrium: evidence for progesterone resistance. Semin Reprod Med 2010;28:51–8.CrossrefGoogle Scholar

  • 89.

    Piltonen TT, Chen JC, Khatun M, Kangasniemi M, Liakka A, Spitzer T, Tran N, Huddleston H, Irwin JC, Giudice LC. Endometrial stromal fibroblasts from women with polycystic ovary syndrome have impaired progesterone-mediated decidualization, aberrant cytokine profiles and promote enhanced immune cell migration in vitro. Hum Reprod 2015;30:1203–15.CrossrefGoogle Scholar

  • 90.

    Savaris RF, Groll JM, Young SL, DeMayo FJ, Jeong JW, Hamilton AE, Giudice LC, Lessey BA. Progesterone resistance in pcos endometrium: a microarray analysis in clomiphene citrate-treated and artificial menstrual cycles. J Clin Endocrinol Metab 2011;96:1737–46.CrossrefGoogle Scholar

  • 91.

    Villavicencio A, Bacallao K, Avellaira C, Fuentes A, Vega M, Gabler F, Wu MH, Lu CW, Chang FM, Tsai SJ, Taylor AH, Al-Azzawi F. Androgen and estrogen receptors and co-regulators levels in endometria from patients with polycystic ovarian syndrome with and without endometrial hyperplasia. 2000. p. 307; 50; 145–314; 54; 155.Google Scholar

  • 92.

    Bulun SE, Chen D, Lu M, Zhao H, Cheng Y, Demura M, Yilmaz B, Martin R, Utsunomiya H, Thung S, Su E, Marsh E, Hakim A, Yin P, Ishikawa H, Amin S, Imir G, Gurates B, Attar E, Reierstad S, Innes J, Lin Z. Aromatase excess in cancers of breast, endometrium and ovary. J Steroid Biochem Mol Biol 2007;106:81–96.CrossrefGoogle Scholar

  • 93.

    Livadas S, Pappas C, Karachalios A, Marinakis E, Tolia N, Drakou M, Kaldrymides P, Panidis D, Diamanti-Kandarakis E. Prevalence and impact of hyperandrogenemia in 1,218 women with polycystic ovary syndrome. Endocrine 2014;47:631–8.Google Scholar

  • 94.

    Kaaks R, Lukanova A, Kurzer MS. Obesity, endogenous hormones, and endometrial cancer risk: a synthetic review. Cancer Epidemiol Biomarkers Prev 2002;11:1531–43.Google Scholar

  • 95.

    Montgomery BE, Daum GS, Dunton CJ. Endometrial hyperplasia: a review. Obstet Gynecol Surv 2004;59:368–78.CrossrefGoogle Scholar

  • 96.

    Mazur MT. Endometrial hyperplasia/adenocarcinoma. A conventional approach. Ann Diagn Pathol 2005;9:174–81.CrossrefGoogle Scholar

  • 97.

    Lacey JV, Jr., Ioffe OB, Ronnett BM, Rush BB, Richesson DA, Chatterjee N, Langholz B, Glass AG, Sherman ME. Endometrial carcinoma risk among women diagnosed with endometrial hyperplasia: the 34-year experience in a large health plan. Br J Cancer 2007;98:45–53.Google Scholar

  • 98.

    Chernyshova AL, Kolomiets LA, Bochkareva NV, Kondakova IV. [Specifics of hormonal and energy balance in patients with hyperplasia and endometrial neoplasia with metabolic syndrome in the background]. Vopr Onkol 2013;59:65–71.Google Scholar

  • 99.

    Jnne O, Kauppila A, Kontula K, Syrjl SP, Vihko R. Female sex steroid receptors in normal, hyperplastic and carcinomatous endometrium. The relationship to serum steroid hormones and gonadotropins and changes during medroxyprogesterone acetate administration. Int J Cancer 1979;24:545–54.CrossrefGoogle Scholar

  • 100.

    Zhao P-L, Zhang Q-F, Yan L-Y, Huang S, Chen Y, Qiao J. Functional investigation on aromatase in endometrial hyperplasia in polycystic ovary syndrome cases. Asian Pac J Cancer Prev 2014;15:8975–9.Google Scholar

  • 101.

    Šmuc T, Rižner TL. Aberrant pre-receptor regulation of estrogen and progesterone action in endometrial cancer. Mol Cell Endocrinol 2009;301:74–82.Google Scholar

  • 102.

    Eritja N, Mirantes C, Llobet D, Yeramian A, Bergada L, Dosil MA, Domingo M, Matias-Guiu X, Dolcet X. Long-term estradiol exposure is a direct mitogen for insulin/egf-primed endometrial cells and drives pten loss-induced hyperplasic growth. Am J Pathol 2013;183:277–87.CrossrefGoogle Scholar

  • 103.

    Dznelashvili NO, Kasradze DG, Tavartkiladze AG, Mariamidze AG, Dzhinchveladze DN. [Expression of epidermal growth factor receptor and plasmatic level of melatonin in simple and complex endometrial hyperplasia]. Georgian Med News 2013:91–5.Google Scholar

  • 104.

    Bhaskaran K, Douglas I, Forbes H, dos-Santos-Silva I, Leon DA, Smeeth L. Body-mass index and risk of 22 specific cancers: a population-based cohort study of 5·24 million uk adults. Lancet 2014;384:755–65.CrossrefGoogle Scholar

  • 105.

    Burleigh A, Talhouk A, Gilks CB, McAlpine JN. Clinical and pathological characterization of endometrial cancer in young women: identification of a cohort without classical risk factors. Gynecol Oncol 2015;138:141–6.Google Scholar

  • 106.

    Keum N, Greenwood D, Hoon Lee D, Kim R, Aune D, Ju W, Hu F, Giovannucci E. Adult weight gain and adiposity-related cancers: a dose-response meta-analysis of prospective observational studies. J Natl Cancer Inst 2015;107.CrossrefGoogle Scholar

  • 107.

    Dougan MM, Hankinson SE, Vivo ID, Tworoger SS, Glynn RJ, Michels KB. Prospective study of body size throughout the life-course and the incidence of endometrial cancer among premenopausal and postmenopausal women. Int J Cancer 2015;137:625–37.CrossrefGoogle Scholar

  • 108.

    Canchola A, Chang E, Bernstein L, Largent J, Reynolds P, Deapen D, Ursin G, Horn-Ross P. Body size and the risk of endometrial cancer by hormone therapy use in postmenopausal women in the california teachers study cohort. Cancer Causes Control 2010;21:1407–16.CrossrefGoogle Scholar

  • 109.

    Benedetto C, Salvagno F, Canuto EM, Gennarelli G. Obesity and female malignancies. Best Pract Res Clin Obstet Gynaecol 2015;29:528–40.CrossrefGoogle Scholar

  • 110.

    Ali AT. Risk factors for endometrial cancer. Ceska Gynekol 2013;78:448–59.Google Scholar

  • 111.

    Simpson ER. Sources of estrogen and their importance. J Steroid Biochem Mol Biol 2003;86:225–30.CrossrefGoogle Scholar

  • 112.

    Ashizawa N, Yahata T, Quan J, Adachi S, Yoshihara K, Tanaka K. Serum leptin–adiponectin ratio and endometrial cancer risk in postmenopausal female subjects. Gynecol Oncol 2010;119:65–9.CrossrefGoogle Scholar

  • 113.

    Luhn P, Dallal CM, Weiss JM, Black A, Huang W-Y, Lacey JV, Hayes RB, Stanczyk FZ, Wentzensen N, Brinton LA. Circulating adipokine levels and endometrial cancer risk in the prostate, lung, colorectal and ovarian cancer screening trial. Cancer Epidemiol Biomarkers Prev 2013;22:1304–12.CrossrefGoogle Scholar

  • 114.

    Moon H-S, Chamberland JP, Aronis K, Tseleni-Balafouta S, Mantzoros CS. Direct role of adiponectin and adiponectin receptors in endometrial cancer: in vitro and ex vivo studies in humans. Mol Cancer Ther 2011;10:2234–43.CrossrefGoogle Scholar

  • 115.

    Cong L, Gasser J, Zhao J, Yang B, Li F, Zhao AZ. Human adiponectin inhibits cell growth and induces apoptosis in human endometrial carcinoma cells, hec-1-a and rl95–2. Endocr Relat Cancer 2007;14:713–20.CrossrefGoogle Scholar

  • 116.

    Maso LD, Augustin LS, Karalis A, Talamini R, Franceschi S, Trichopoulos D, Mantzoros CS, Vecchia CL. Circulating adiponectin and endometrial cancer risk. J Clin Endocrinol Metab 2004;89:1160–3.CrossrefGoogle Scholar

  • 117.

    Kishida K, Funahashi T, Shimomura I. Adiponectin as a routine clinical biomarker. Best Pract Res Clin Endocrinol Metab 2014;28:119–30.CrossrefGoogle Scholar

  • 118.

    Chen X, Xiang Y-B, Long J-R, Cai H, Cai Q, Cheng J, Wen W, Gao Y-T, Zheng W, Shu X-O. Genetic polymorphisms in obesity-related genes and endometrial cancer risk. Cancer 2012;118:3356–64.CrossrefGoogle Scholar

  • 119.

    Garofalo C, Surmacz E. Leptin and cancer. J Cell Physiol 2006;207:12–22.CrossrefGoogle Scholar

  • 120.

    Linkov F, Burke LE, Komaroff M, Edwards RP, Lokshin A, Styn MA, Tseytlin E, Freese KE, Bovbjerg DH. An exploratory investigation of links between changes in adipokines and quality of life in individuals undergoing weight loss interventions: possible implications for cancer research. Gynecol Oncol 2014;133:67–72.CrossrefGoogle Scholar

  • 121.

    Friberg E, Orsini N, Mantzoros CS, Wolk A. Diabetes mellitus and risk of endometrial cancer: a meta-analysis. Diabetologia 2007;50:1365–74.CrossrefGoogle Scholar

  • 122.

    Mantzoros CS. Obesity and diabetes. [electronic book]: Totowa, NJ: Humana Press, 2006.Google Scholar

  • 123.

    Markowska A, Pawalowska M, Filas V, Korski K, Grybos M, Sajdak S, Olejek A, Bednarek W, Spiewankiewicz B, Lubin J, Markowska J. Does metformin affect er, pr, igf-1r, beta-catenin and pax-2 expression in women with diabetes mellitus and endometrial cancer? Diabetol Metab Syndr 2013;5:76.CrossrefGoogle Scholar

  • 124.

    Hendriks YM, Wagner A, Morreau H, Menko F, Stormorken A, Quehenberger F, Sandkuijl L, Moller P, Genuardi M, Van Houwelingen H, Tops C, Van Puijenbroek M, Verkuijlen P, Kenter G, Van Mil A, Meijers-Heijboer H, Tan GB, Breuning MH, Fodde R, Wijnen JT, Brocker-Vriends AH, Vasen H. Cancer risk in hereditary nonpolyposis colorectal cancer due to msh6 mutations: impact on counseling and surveillance. Gastroenterology 2004;127:17–25.CrossrefGoogle Scholar

  • 125.

    Tafe LJ. Targeted next-generation sequencing for hereditary cancer syndromes: a focus on lynch syndrome and associated endometrial cancer. J Mol Diagn 2015;17:472–82.CrossrefGoogle Scholar

  • 126.

    Goodfellow PJ, Billingsley CC, Lankes HA, Ali S, Cohn DE, Broaddus RJ, Ramirez N, Pritchard CC, Hampel H, Chassen AS, Simmons LV, Schmidt AP, Gao F, Brinton LA, Backes F, Landrum LM, Geller MA, DiSilvestro PA, Pearl ML, Lele SB, Powell MA, Zaino RJ, Mutch D. Combined microsatellite instability, mlh1 methylation analysis, and immunohistochemistry for lynch syndrome screening in endometrial cancers from gog210: an nrg oncology and gynecologic oncology group study. J Clin Oncol 2015;33:4301–8.CrossrefGoogle Scholar

  • 127.

    Douglas JA, Gruber SB, Meister KA, Bonner J, Watson P, Krush AJ, Lynch HT. History and molecular genetics of lynch syndrome in family g: a century later. J Am Med Assoc 2005;294:2195–202.CrossrefGoogle Scholar

  • 128.

    Miyamoto T, Shiozawa T, Kashima H, Feng YZ, Suzuki A, Kurai M, Nikaido T, Konishi I. Estrogen up-regulates mismatch repair activity in normal and malignant endometrial glandular cells. Endocrinology 2006;147:4863–70.CrossrefGoogle Scholar

  • 129.

    Kane MF, Loda M, Gaida GM, Lipman J, Mishra R, Goldman H, Jessup JM, Kolodner R. Methylation of the hmlh1 promoter correlates with lack of expression of hmlh1 in sporadic colon tumors and mismatch repair-defective human tumor cell lines. Cancer Res 1997;57:808–11.Google Scholar

  • 130.

    Dashti SG, Chau R, Ouakrim DA, Buchanan DD, Clendenning M, Young JP, Winship IM, Arnold J, Ahnen DJ, Haile RW, Casey G, Gallinger S, Thibodeau SN, Lindor NM, Le Marchand L, Newcomb PA, Potter JD, Baron JA, Hopper JL, Jenkins MA, Win AK. Female hormonal factors and the risk of endometrial cancer in lynch syndrome. J Am Med Assoc 2015;314:61–71.CrossrefGoogle Scholar

  • 131.

    Cancer Research UK. Available from: http://www.cancerresearchuk.org/health-professional/uterine-cancer-risk-factors#heading-Eightteen. Accessed January 2016.

  • 132.

    Felix AS, Yang HP, Gierach GL, Park Y, Brinton LA. Cigarette smoking and endometrial carcinoma risk: the role of effect modification and tumor heterogeneity. Cancer Causes Control 2014;25:479–89.CrossrefGoogle Scholar

  • 133.

    Michnovicz JJ, Hershcopf RJ, Naganuma H, Bradlow HL, Fishman J. Increased 2-hydroxylation of estradiol as a possible mechanism for the anti-estrogenic effect of cigarette smoking. N Engl J Med 1986;315:1305–9.CrossrefGoogle Scholar

  • 134.

    Mattison DR, Thorgeirsson SS. Smoking and industrial pollution, and their effects on menopause and ovarian cancer. Lancet (London, England) 1978;1:187–8.CrossrefGoogle Scholar

  • 135.

    Spangler JG. Smoking and hormone-related disorders. Prim Care 1999;26:499–511.CrossrefGoogle Scholar

  • 136.

    Khaw KT, Tazuke S, Barrett-Connor E. Cigarette smoking and levels of adrenal androgens in postmenopausal women. N Engl J Med 1988;318:1705–9.CrossrefGoogle Scholar

  • 137.

    Kapoor D, Jones TH. Smoking and hormones in health and endocrine disorders. Eur J Endocrinol 2005;152:491–9.CrossrefGoogle Scholar

  • 138.

    Brand JS, Chan MF, Dowsett M, Folkerd E, Wareham NJ, Luben RN, van der Schouw YT, Khaw KT. Cigarette smoking and endogenous sex hormones in postmenopausal women. J Clin Endocrinol Metab 2011;96:3184–92.CrossrefGoogle Scholar

  • 139.

    Polesel J, Serraino D, Zucchetto A, Lucenteforte E. Cigarette smoking and endometrial cancer risk: the modifying effect of obesity. Eur J Cancer Prev 2009;18:476–81.CrossrefGoogle Scholar

  • 140.

    Minami Y, Yamamoto R, Nishikouri M, Fukao A, Hisamichi S. Mortality and cancer incidence in patients with parkinson’s disease. J Neurol 2000;247:429–34.Google Scholar

  • 141.

    Currie LJ, Harrison MB, Trugman JM, Bennett JP, Wooten GF. Postmenopausal estrogen use affects risk for parkinson disease. Arch Neurol 2004;61:886–8.CrossrefGoogle Scholar

  • 142.

    Bourque M, Dluzen DE, Di Paolo T. Neuroprotective actions of sex steroids in parkinson’s disease. Front Neuroendocrinol 2009;30:142–57.CrossrefGoogle Scholar

  • 143.

    Ekue A, Boulanger JF, Morissette M, Di Paolo T. Lack of effect of testosterone and dihydrotestosterone compared to 17beta-oestradiol in 1-methyl-4-phenyl-1,2,3,6, tetrahydropyridine-mice. J Neuroendocrinol 2002;14:731–6.CrossrefGoogle Scholar

  • 144.

    Yu L, Liao PC. Estrogen and progesterone distinctively modulate methamphetamine-induced dopamine and serotonin depletions in C57BL/6J mice. J Neural Transm (Vienna) 2000;107:1139–47.CrossrefGoogle Scholar

  • 145.

    Ong EL, Goldacre R, Goldacre M. Differential risks of cancer types in people with parkinson’s disease: a national record-linkage study. Eur J Cancer 2014;50:2456–62.CrossrefGoogle Scholar

  • 146.

    Mueck AO, Seeger H, Rabe T. Hormonal contraception and risk of endometrial cancer: a systematic review. Endocr Relat Cancer 2010;17:R263–71.CrossrefGoogle Scholar

  • 147.

    Endometrial cancer and oral contraceptives: an individual participant meta-analysis of 27 276 women with endometrial cancer from 36 epidemiological studies. Lancet Oncol 2015:1061–70.Google Scholar

  • 148.

    Cook LS, Dong Y, Round P, Huang X, Magliocco AM, Friedenreich CM. Hormone contraception before the first birth and endometrial cancer risk. Cancer Epidemiol Biomarkers Prev 2014;23:356–61.CrossrefGoogle Scholar

  • 149.

    Maxwell GL, Schildkraut JM, Calingaert B, Risinger JI, Dainty L, Marchbanks PA, Berchuck A, Barrett JC, Rodriguez GC. Progestin and estrogen potency of combination oral contraceptives and endometrial cancer risk. Gynecol Oncol 2006;103:535–40.CrossrefGoogle Scholar

  • 150.

    Kaunitz AM. Depot medroxyprogesterone acetate contraception and the risk of breast and gynecologic cancer. J Reprod Med 1996;41:419–27.Google Scholar

  • 151.

    Soini T, Hurskainen R, Grénman S, Mäenpää J, Paavonen J, Pukkala E. Cancer risk in women using the levonorgestrel-releasing intrauterine system in finland. Obstet Gynecol 2014;124:292–9.CrossrefGoogle Scholar

  • 152.

    Chlebowski RT, Anderson GL. Menopausal hormone therapy and cancer: changing clinical observations of target site specificity. Steroids 2014;90:53–9.CrossrefGoogle Scholar

  • 153.

    Morch LS, Kjaer SK, Keiding N, Lokkegaard E, Lidegaard O. The influence of hormone therapies on type i and ii endometrial cancer: a nationwide cohort study. Int J Cancer 2016;138:1506–15.CrossrefGoogle Scholar

  • 154.

    Fournier A, Dossus L, Mesrine S, Vilier A, Boutron-Ruault MC, Clavel-Chapelon F, Chabbert-Buffet N. Risks of endometrial cancer associated with different hormone replacement therapies in the e3n cohort, 1992–2008. Am J Epidemiol 2014;180:508–17.Google Scholar

  • 155.

    Shim SH, Lee SJ, Kim SN. Effects of hormone replacement therapy on the rate of recurrence in endometrial cancer survivors: a meta-analysis. Eur J Cancer 2014;50:1628–37.CrossrefGoogle Scholar

  • 156.

    Behnamfar F, Ghahiri A, Tavakoli M. Levonorgestrel-releasing intrauterine system (mirena) in compare to medroxyprogesterone acetate as a therapy for endometrial hyperplasia. J Res Med Sci 2014;19:686–90.Google Scholar

  • 157.

    Lai CH, Huang HJ. The role of hormones for the treatment of endometrial hyperplasia and endometrial cancer. Curr Opin Obstet Gynecol 2006;18:29–34.Google Scholar

  • 158.

    Gallos ID, Krishan P, Shehmar M, Ganesan R, Gupta JK. Lng-ius versus oral progestogen treatment for endometrial hyperplasia: a long-term comparative cohort study. Hum Reprod 2013;28:2966–71.CrossrefGoogle Scholar

  • 159.

    Gallos ID, Krishan P, Shehmar M, Ganesan R, Gupta JK. Relapse of endometrial hyperplasia after conservative treatment: a cohort study with long-term follow-up. Hum Reprod 2013;28:1231–6.CrossrefGoogle Scholar

  • 160.

    Park JY, Nam JH. Progestins in the fertility-sparing treatment and retreatment of patients with primary and recurrent endometrial cancer. Oncologist 2015;20:270–8.CrossrefGoogle Scholar

  • 161.

    Colombo N, Preti E, Landoni F, Carinelli S, Colombo A, Marini C, Sessa C, Group EG. Endometrial cancer: esmo clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2013;24 Suppl 6:vi33–8.CrossrefGoogle Scholar

  • 162.

    Martin-Hirsch PP, Bryant A, Keep SL, Kitchener HC, Lilford R. Adjuvant progestagens for endometrial cancer. Cochrane Database Syst Rev 2011:Cd001040.Google Scholar

  • 163.

    Slayden OD. Progesterone antagonists increase androgen receptor expression in the rhesus macaque and human endometrium. J Clin Endocrinol Metab 2001;86:2668.Google Scholar

  • 164.

    Spitz IM, Grunberg SM, Chabbert-Buffet N, Lindenberg T, Gelber H, Sitruk-Ware R. Management of patients receiving long-term treatment with mifepristone. Fertil Steril 2005;84:1719–26.CrossrefGoogle Scholar

  • 165.

    Romero-Pérez L, Díaz-Martín J, López-García MA, Castilla MA, Palacios J, Garcia-Sanz P, Mota A, Hergueta-Redondo M, Moreno-Bueno G, Leskelä S, Martínez-Ramírez A, Soslow RA, Matias-Guiu X. A role for the transducer of the hippo pathway, taz, in the development of aggressive types of endometrial cancer. Mod Pathol 2015;28:1492–503.CrossrefGoogle Scholar

  • 166.

    Ramondetta LM, Johnson AJ, Sun CC, Atkinson N, Smith JA, Jung MS, Broaddus R, Iyer RB, Burke T. Phase 2 trial of mifepristone (ru-486) in advanced or recurrent endometrioid adenocarcinoma or low-grade endometrial stromal sarcoma. Cancer 2009;115:1867–74.CrossrefGoogle Scholar

  • 167.

    Grunberg SM, Weiss MH, Russell CA, Spitz IM, Ahmadi J, Sadun A, Sitruk-Ware R. Long-term administration of mifepristone (ru486): clinical tolerance during extended treatment of meningioma. Cancer Invest 2006;24:727–33.CrossrefGoogle Scholar

  • 168.

    Ellis AJ, Hendrick VM, Williams R, Komm BS. Selective estrogen receptor modulators in clinical practice: a safety overview. Expert Opin Drug Saf 2015;14:921–34.CrossrefGoogle Scholar

  • 169.

    Cohen I. Endometrial pathologies associated with postmenopausal tamoxifen treatment. Gynecol Oncol 2004;94:256–66.CrossrefGoogle Scholar

  • 170.

    Committee opinion no. 601. Tamoxifen and uterine cancer. Obstet Gynecol 2014;123:1394–7.PubMedGoogle Scholar

  • 171.

    Mirkin S, Pickar JH. Selective estrogen receptor modulators (serms): a review of clinical data. Maturitas 2015;80:52–7.CrossrefGoogle Scholar

  • 172.

    Nakamura K, Sawada K, Sugiyama M, Mabuchi S, Hisamatsu T, Nishio Y, Ito K, Kimura T, Kamiura S, Morishige K. Efficacy of raloxifene hydrochloride for the prevention of health care problems in patients who undergo surgery for endometrial cancer: a multicenter randomized clinical trial. Int J Gynecol Cancer 2015;25:288–95.CrossrefGoogle Scholar

  • 173.

    Constantine GD, Goldstein SR, Archer DF. Endometrial safety of ospemifene: results of the phase 2/3 clinical development program. Menopause 2015;22:36–43.Google Scholar

  • 174.

    Gennari L. Lasofoxifene, a new selective estrogen receptor modulator for the treatment of osteoporosis and vaginal atrophy. Expert Opin Pharmacother 2009;10:2209–20.CrossrefGoogle Scholar

  • 175.

    Archer DF, Hendrix S, Ferenczy A, Felix J, Gallagher JC, Rymer J, Skouby SO, den Hollander W, Stathopoulos V, Helmond FA. Tibolone histology of the endometrium and breast endpoints study: design of the trial and endometrial histology at baseline in postmenopausal women. Fertil Steril 2007;88:866–78.CrossrefGoogle Scholar

  • 176.

    Morales L, Neven P, Timmerman D, Wildiers H, Konstantinovic ML, Christiaens MR, Tan PN, Paridaens R. Prospective assessment of the endometrium in postmenopausal breast cancer patients treated with fulvestrant. Breast Cancer Res Treat 2009;117:77–81.CrossrefGoogle Scholar

  • 177.

    Covens AL, Filiaci V, Gersell D, Lutman CV, Bonebrake A, Lee YC. Phase ii study of fulvestrant in recurrent/metastatic endometrial carcinoma: a gynecologic oncology group study. Gynecol Oncol 2011;120:185–8.CrossrefGoogle Scholar

  • 178.

    Emons G, Günthert A, Thiel FC, Camara O, Strauss H-G, Breitbach G-P, Kölbl H, Reimer T, Finas D, Rensing K. Phase ii study of fulvestrant 250 mg/month in patients with recurrent or metastatic endometrial cancer: a study of the arbeitsgemeinschaft gynäkologische onkologie. Gynecol Oncol 2013;129:495–9.CrossrefGoogle Scholar

  • 179.

    Garuti G, Cellani F, Centinaio G, Montanari G, Nalli G, Luerti M. Prospective endometrial assessment of breast cancer patients treated with third generation aromatase inhibitors. Gynecol Oncol 2006;103:599–603.CrossrefGoogle Scholar

  • 180.

    Agorastos T, Vaitsi V, Pantazis K, Efstathiadis E, Vavilis D, Bontis JN. Aromatase inhibitor anastrozole for treating endometrial hyperplasia in obese postmenopausal women. Eur J Obstet Gynecol Reprod Biol 2005;118:239–40.CrossrefGoogle Scholar

  • 181.

    Barker LC, Brand IR, Crawford SM. Sustained effect of the aromatase inhibitors anastrozole and letrozole on endometrial thickness in patients with endometrial hyperplasia and endometrial carcinoma. Curr Med Res Opin 2009;25:1105–9.CrossrefGoogle Scholar

  • 182.

    Carlson MJ, Thiel KW, Leslie KK. Past, present, and future of hormonal therapy in recurrent endometrial cancer. Int J Womens Health 2014;6:429–35.Google Scholar

  • 183.

    Ma BB, Oza A, Eisenhauer E, Stanimir G, Carey M, Chapman W, Latta E, Sidhu K, Powers J, Walsh W, Fyles A. The activity of letrozole in patients with advanced or recurrent endometrial cancer and correlation with biological markers – a study of the national cancer institute of canada clinical trials group. Int J Gynecol Cancer 2004;14:650–8.CrossrefGoogle Scholar

  • 184.

    Rose PG, Brunetto VL, VanLe L, Bell J, Walker JL, Lee RB. Regular article: a phase ii trial of anastrozole in advanced recurrent or persistent endometrial carcinoma: a gynecologic oncology group study. Gynecol Oncol 2000;78:212–6.CrossrefGoogle Scholar

  • 185.

    Maclaran K, Panay N. The safety of postmenopausal testosterone therapy. Womens Health (Lond Engl) 2012;8:263–75.CrossrefGoogle Scholar

  • 186.

    Manley K, Edey K, Braybrooke J, Murdoch J. Hormone replacement therapy after endometrial cancer. Menopause Int 2012;18:134–8.Google Scholar

  • 187.

    Perrone AM, Cerpolini S, Maria Salfi NC, Ceccarelli C, De Giorgi LB, Formelli G, Casadio P, Ghi T, Pelusi G, Pelusi C, Meriggiola MC. Effect of long-term testosterone administration on the endometrium of female-to-male (ftm) transsexuals. J Sex Med 2009;6:3193–200.CrossrefGoogle Scholar

  • 188.

    Portman DJ, Labrie F, Archer DF, Bouchard C, Cusan L, Girard G, Ayotte N, Koltun W, Blouin F, Young D, Wade A, Martel C, Dube R. Lack of effect of intravaginal dehydroepiandrosterone (dhea, prasterone) on the endometrium in postmenopausal women. Menopause 2015;22:1289–95.CrossrefGoogle Scholar

  • 189.

    Tanaka T, Umesaki N. Danazol enhances fas-mediated apoptosis in human endometrial epithelial cells within normal physiology. Int J Mol Med 2009;23:237–43.Google Scholar

  • 190.

    Terakawa N, Ikegami H, Shimizu I, Aono T, Tanizawa O, Matsumoto K. Growth inhibition by danazol in a human endometrial cancer cell line with estrogen-independent progesterone receptors. J Steroid Biochem 1987;28:571–4.CrossrefGoogle Scholar

  • 191.

    Surrey ES, Halme J. Direct effects of medroxyprogesterone acetate, danazol, and leuprolide acetate on endometrial stromal cell proliferation in vitro. Fertil Steril 1992;58:273–8.CrossrefGoogle Scholar

  • 192.

    Niwa K, Hashimoto M, Morishita S, Yokoyama Y, Lian Z, Tagami K, Mori H, Tamaya T. Preventive effects of danazol on endometrial carcinogenesis in mice. Cancer Lett 2000;158:133–9.CrossrefGoogle Scholar

  • 193.

    Tamaoka Y, Orikasa H, Sumi Y, Sakakura K, Kamei K, Nagatani M, Ezawa S. Treatment of endometrial hyperplasia with a danazol-releasing intrauterine device: a prospective study. Gynecol Obstet Invest 2004;58:42–8.CrossrefGoogle Scholar

  • 194.

    Mariani L, Sedati A, Giovinazzi R, Sindico R, Atlante G. Postmenopausal endometrial hyperplasia: role of danazol therapy. Int J Gynaecol Obstet 1994;44:155–9.CrossrefGoogle Scholar

  • 195.

    Covens A, Brunetto VL, Markman M, Orr JW, Lentz SS, Benda J. Phase ii trial of danazol in advanced, recurrent, or persistent endometrial cancer: a gynecologic oncology group study. Gynecol Oncol 2003;89:470–4.CrossrefGoogle Scholar

  • 196.

    Montagnani Marelli M, Moretti RM, Januszkiewicz-Caulier J, Motta M, Limonta P. Gonadotropin-releasing hormone (gnrh) receptors in tumors: a new rationale for the therapeutical application of gnrh analogs in cancer patients? Curr Cancer Drug Targets 2006;6:257–69.CrossrefGoogle Scholar

  • 197.

    Grundker C, Gunthert AR, Westphalen S, Emons G. Biology of the gonadotropin-releasing hormone system in gynecological cancers. Eur J Endocrinol 2001;146:1–14.CrossrefGoogle Scholar

  • 198.

    Grundker C, Schlotawa L, Viereck V, Emons G. Protein kinase c-independent stimulation of activator protein-1 and c-jun n-terminal kinase activity in human endometrial cancer cells by the lhrh agonist triptorelin. Eur J Endocrinol 2001;145:651–8.CrossrefGoogle Scholar

  • 199.

    Herbst KL. Gonadotropin-releasing hormone antagonists. Curr Opin Pharmacol 2003;3:660–6.CrossrefGoogle Scholar

About the article

Corresponding author: Dharani K. Hapangama, Institute of Translational Medicine, Department of Women’s and Children’s Health, University of Liverpool, Liverpool, L7 8SS, UK, Phone: +44 151 7959559, Fax: +44 151 795 9599, E-mail: ; and Liverpool Women’s Hospital NHS Foundation Trust, Liverpool, UK


Received: 2016-01-12

Accepted: 2016-02-05

Published Online: 2016-03-11

Published in Print: 2016-02-01


Citation Information: Hormone Molecular Biology and Clinical Investigation, Volume 25, Issue 2, Pages 129–148, ISSN (Online) 1868-1891, ISSN (Print) 1868-1883, DOI: https://doi.org/10.1515/hmbci-2016-0005.

Export Citation

©2016 by De Gruyter.Get Permission

Comments (0)

Please log in or register to comment.
Log in